Arndt Schottelius

Chief Executive Officer
Maxion Therapeutics

Prior to joining Maxion, Arndt has served as the Chief Scientific Officer of Affimed and held executive leadership roles as Executive Vice President of R&D at Kymab (acquired by Sanofi) and Chief Development Officer at MorphoSys as well as senior leadership roles at Genentech. During his 25-year career in the pharmaceutical industry, he established a successful track record of advancing therapeutics from research into early and late-stage clinical developments and in building valuable portfolios of drug candidates and pharma partnerships.